Kim Sung Wook, Jeong Soo Hyun, Kim Jong Uk, Kim Mi Hye, Lee Wonwoong, Lee Cheol-Jung, Yook Tae Han, Yang Gabsik
College of Korea Medicine, Woosuk University, Jeonju-si 54986, Republic of Korea.
Department of Pharmacy, College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea.
Pharmaceuticals (Basel). 2024 Dec 29;18(1):29. doi: 10.3390/ph18010029.
Monosodium urate crystal accumulation in the joints is the cause of gout, an inflammatory arthritis that is initiated by elevated serum uric acid levels. It is the most prevalent form of inflammatory arthritis, affecting millions worldwide, and requires effective treatments. The necessity for alternatives with fewer side effects is underscored by the frequent adverse effects of conventional therapies, such as urate-lowering drugs. IL-1β is a potential therapeutic target due to its significant role in the inflammatory response induced by MSU. Benn. (ZP), a shrub that possesses antibacterial, antioxidant, and anti-inflammatory properties, has demonstrated potential in the treatment of inflammatory conditions. For anti-inflammatory properties of ZP, Raw264.7 cell stimulated LPS were treated ZP and using RNA-seq with Bone marrow derived macrophage, we observed to change inflammatory gene. Pharmacological networks were conducted to select target gene associated with ZP. For in vivo, mice were injected MSU in footpad for induce gouty arthritis model. The components of ZP were analyzed using GC-MS, and distilled extracts of ZP (deZP) were prepared. In vitro, deZP decreased inflammatory cytokines. However, in vivo, it also decreased paw thickness and IL-1β levels. The anti-inflammatory effects of deZP are believed to be mediated through the NLRP3 inflammasome pathway, as indicated by RNA sequencing and network pharmacology analyses. ZP has an anti-inflammatory effect and regulation of the NLRP3 inflammasome in vitro and in vivo. Further research, including clinical trials, is required to confirm the safety of deZP, determine the optimal dosing, and evaluate its long-term effects.
关节中尿酸钠晶体的积累是痛风的病因，痛风是一种由血清尿酸水平升高引发的炎症性关节炎。它是炎症性关节炎最常见的形式，全球数百万人受其影响，需要有效的治疗方法。传统疗法（如降尿酸药物）频繁出现的不良反应凸显了开发副作用更少的替代疗法的必要性。IL-1β因其在尿酸钠诱导的炎症反应中起重要作用而成为一个潜在的治疗靶点。Benn.（ZP）是一种具有抗菌、抗氧化和抗炎特性的灌木，已显示出在治疗炎症性疾病方面的潜力。对于ZP的抗炎特性，用LPS刺激Raw264.7细胞后用ZP处理，并使用骨髓来源的巨噬细胞进行RNA测序，我们观察到炎症基因发生了变化。构建药理学网络以筛选与ZP相关的靶基因。在体内实验中，将尿酸钠注射到小鼠足垫中以诱导痛风性关节炎模型。用气相色谱-质谱联用仪分析ZP的成分，并制备ZP的蒸馏提取物（deZP）。在体外，deZP降低了炎症细胞因子水平。然而，在体内，它也降低了爪厚度和IL-1β水平。RNA测序和网络药理学分析表明，deZP的抗炎作用可能是通过NLRP3炎性小体途径介导的。ZP在体外和体内均具有抗炎作用并能调节NLRP3炎性小体。需要进一步开展研究（包括临床试验）来确认deZP的安全性、确定最佳剂量并评估其长期效果。
